In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1
Open Access
- 1 February 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 6 (2) , 450-459
Abstract
Polo-like kinase 1 (PLK1) plays key roles in the regulation of mitotic progression, including mitotic entry, spindle formation, chromosome segregation, and cytokinesis. PLK1 expression and activity are strongly linked to proliferating cells. Many studies have shown that PLK1 expression is elevated in a variety of tumors, and high expression often correlates with poor prognosis. Using a variety of methods, including small-molecule inhibition of PLK1 function and/or activity, apoptosis in cancer cell lines, cell cycle arrest in normal cell lines, and antitumor activity in vivo have been observed. In the present study, we have examined the in vitro biological activity of a novel and selective thiophene benzimidazole ATP-competitive inhibitor of PLK1 and PLK3 (5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-{[2-(trifluoromethyl)-benzyl]oxy}thiophene-2-carboxamide, called compound 1). Compound 1 has low nanomolar activity against the PLK1 and PLK3 enzymes and potently inhibits the proliferation of a wide variety of tumor cell lines. In the lung adenocarcinoma cell line NCI-H460, compound 1 induces a transient G2-M arrest, mitotic spindle defects, and a multinucleate phenotype resulting in apoptosis, whereas normal human diploid fibroblasts arrest in G2-M and show little apoptosis. We also describe a cellular mechanistic assay that was developed to identify potent intracellular inhibitors of PLK1. In addition to its potential as a therapeutic agent for treating cancer, compound 1 is also a useful tool molecule for further investigation of the biological functions of PLK1 and PLK3. [Mol Cancer Ther 2007;6(2):450–9]Keywords
This publication has 30 references indexed in Scilit:
- Targeting polo-like kinase 1 for cancer therapyNature Reviews Cancer, 2006
- Molecular alterations after Polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cellsMolecular Cancer Therapeutics, 2006
- ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agentCancer Cell, 2005
- Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1Oncogene, 2005
- Polo-like kinases and the orchestration of cell divisionNature Reviews Molecular Cell Biology, 2004
- A Role for Plk1 Phosphorylation of NudC in CytokinesisDevelopmental Cell, 2003
- Tumor regression by combination antisense therapy against Plk1 and Bcl-2Oncogene, 2003
- Phosphorylation of Threonine 210 and the Role of Serine 137 in the Regulation of Mammalian Polo-like KinaseJournal of Biological Chemistry, 2002
- Polo-like kinase1, a New Target for Antisense Tumor TherapyBiochemical and Biophysical Research Communications, 2000
- Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes.Journal of Cell Biology, 1996